CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies
Standard
CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. / Klyuchnikov, Evgeny; El-Cheikh, Jean; Sputtek, Andreas; Lioznov, Michael; Calmels, Boris; Furst, Sabine; Chabannon, Christian; Crocchiolo, Roberto; Lemarié, Claude; Faucher, Catherine; Bacher, Ulrike; Alchalby, Haefaa; Stübig, Thomas; Wolschke, Christine; Ayuketang, Francis Ayuk; Reckhaus, Marie-Luise; Blaise, Didier; Kröger, Nicolaus-Martin.
in: BIOL BLOOD MARROW TR, Jahrgang 20, Nr. 3, 01.03.2014, S. 382-6.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies
AU - Klyuchnikov, Evgeny
AU - El-Cheikh, Jean
AU - Sputtek, Andreas
AU - Lioznov, Michael
AU - Calmels, Boris
AU - Furst, Sabine
AU - Chabannon, Christian
AU - Crocchiolo, Roberto
AU - Lemarié, Claude
AU - Faucher, Catherine
AU - Bacher, Ulrike
AU - Alchalby, Haefaa
AU - Stübig, Thomas
AU - Wolschke, Christine
AU - Ayuketang, Francis Ayuk
AU - Reckhaus, Marie-Luise
AU - Blaise, Didier
AU - Kröger, Nicolaus-Martin
N1 - Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
PY - 2014/3/1
Y1 - 2014/3/1
N2 - We retrospectively analyzed outcomes of a CD34(+)-selected stem cell boost (SCB) without prior conditioning in 32 patients (male/22; median age of 54 years; range, 20 to 69) with poor graft function, defined as neutrophils ≤1.5 x 10(9)/L, and/or platelets ≤30 x 10(9)/L, and/or hemoglobin ≤8.5 g/dL). The median interval between stem cell transplantation and SCB was 5 months (range, 2 to 228). The median number of CD34(+) and CD3(+) cells were 3.4 x 10(6)/kg (.96 to 8.30) and 9 x 10(3)/kg body weight (range, 2 to 70), respectively. Hematological improvement was observed in 81% of patients and noted after a median of 30 days (range, 14 to 120) after SCB. The recipients of related grafts responded faster than recipients of unrelated grafts (20 versus 30 days, P = .04). The cumulative incidence of acute (grade II to IV) and chronic graft-versus-host disease (GVHD) after SCB was 17% and 26%, respectively. Patients with acute GVHD received a higher median CD3(+) cell dose. The 2-year probability of overall survival was 45%. We suggest that SCB represents an effective approach to improve poor graft function post transplantation, but optimal timing of SCB administration, anti-infective, and GVHD prophylaxis needs further evaluation.
AB - We retrospectively analyzed outcomes of a CD34(+)-selected stem cell boost (SCB) without prior conditioning in 32 patients (male/22; median age of 54 years; range, 20 to 69) with poor graft function, defined as neutrophils ≤1.5 x 10(9)/L, and/or platelets ≤30 x 10(9)/L, and/or hemoglobin ≤8.5 g/dL). The median interval between stem cell transplantation and SCB was 5 months (range, 2 to 228). The median number of CD34(+) and CD3(+) cells were 3.4 x 10(6)/kg (.96 to 8.30) and 9 x 10(3)/kg body weight (range, 2 to 70), respectively. Hematological improvement was observed in 81% of patients and noted after a median of 30 days (range, 14 to 120) after SCB. The recipients of related grafts responded faster than recipients of unrelated grafts (20 versus 30 days, P = .04). The cumulative incidence of acute (grade II to IV) and chronic graft-versus-host disease (GVHD) after SCB was 17% and 26%, respectively. Patients with acute GVHD received a higher median CD3(+) cell dose. The 2-year probability of overall survival was 45%. We suggest that SCB represents an effective approach to improve poor graft function post transplantation, but optimal timing of SCB administration, anti-infective, and GVHD prophylaxis needs further evaluation.
U2 - 10.1016/j.bbmt.2013.11.034
DO - 10.1016/j.bbmt.2013.11.034
M3 - SCORING: Journal article
C2 - 24321747
VL - 20
SP - 382
EP - 386
JO - BIOL BLOOD MARROW TR
JF - BIOL BLOOD MARROW TR
SN - 1083-8791
IS - 3
ER -